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Control of rat glomerular epithelial cell growth in vitro
STEPHEN ADLER, X. CHEN, and B. ENG
Division of Nephrology, Department of Medicine, New York Medical College, Valhalla, New York, USA
Control of rat glomerular epithelial cell growth in vitro. The interac-
tion of cultured rat GEC' with several growth factors was explored in
order to obtain a better understanding of in vivo factors which might
stimulate GEC proliferation. GEC proliferated in response to EGF but
not IGF-1, MSA or PDGF. Specific, saturable receptors for EGF were
detected in saturation and competition binding studies utilizing 1251
EGF with an approximate Kd of 1.7 n and 86,000 binding sites per
cell. TGF-/3 inhibited GEC growth in a time and dose dependent manner
with a brief early exposure resulting in prolonged growth inhibition
which was not reversible by EGF. Exposure to TGF-/3 sufficient to
maximally inhibit growth had no effect on EGF binding to GEC. More
prolonged exposure to TGF-/3, however, did result in an increase in the
apparent number of EUF receptors on GEC but no change in Kd. These
studies suggest that EGF and TGF-/3 released by inflammatory cells or
platelets during the course of glomerular injury may play a role in
modulating glomerular cell proliferation.
Proliferation of glomerular cells occurs in response to renal
injury in several different types of human and experimental
renal disease. It is also an important component of the struc-
tural and functional alterations which lead to progressive loss of
renal function even in the absence of acute ongoing injury [1].
Inflammatory cells, platelets and resident glomerular cells
themselves are a potential source of growth factors and cyto-
kines which may be important modulators of glomerular cell
activity. Recent work utilizing cultured glomerular mesangial
and epithelial cells has led to a better understanding of which of
these factors may be involved in the initiation of glomerular cell
growth in vivo [2—4].
Glomerular mesangial cells both secrete and proliferate in
response to several cytokines and growth factors. Production of
PDGF, IGF-l, IL-l and GM-CSF by mesangial cells has been
demonstrated by several groups [5—8]. Proliferation of mesan-
gial cells is stimulated by several growth factors (EGF. PDGF,
bFGF, IGF-l) and cytokines (IL-i, TNF) [5, 6, 9—12]. Several
of these factors are released by macrophages and may explain
some or all of the previously observed stimulatory effects of
macrophage conditioned media on mesangial cell growth [2,
'Abbreviations used are: bFGF-basic fibroblast growth factor; EGF-
epidermal growth factor; GEC-glomerular visceral epithelial cells; GM-
CSF-granulocyte macrophage colony stimulating factor; IGF-l-insulin-like
growth factor-l; IL- l-interleukin- 1; MSA-rat multiplication stimulating
activity; PDGF-platelet-derived growth factor.
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13]. Mesangial cell proliferation is inhibited by PGE2, heparin
and heparan sulfate in vitro and by heparin in vivo [14—17].
TGF-13 displays a biphasic effect on murine mesangial cell
growth in vitro while being inhibitory to epithelial and endothe-
hal cells [18].
The factors which modulate glomerular epithelial cell growth
have not been as extensively defined. Glomerular visceral
epithelial cells (GEC) have been shown to proliferate in re-
sponse to macrophage conditioned media and leukotrienes
LTC4 and LTD4 [19]. The temporal association between influx
of macrophages and crescent development in experimental
models of crescentic nephritis also suggests that products of
inflammatory cells may contribute to GEC proliferation, al-
though the contribution of visceral epithelial cells, especially to
inflammatory crescents, is not universally accepted [201. We
have previously shown that heparin and heparan sulfate are
inhibitors of GEC growth and that EGF can partially reverse
this inhibitory effect [21, 22]. To further explore factors which
modulate GEC growth we have examined the response of GEC
to several growth factors, have studied the binding of EGF to
GEC and examined the growth inhibitory effects of TGF-f3 on
these cells.
Methods
Reagents
Media and additives for culture of rat glomerular visceral
epithelial cells were obtained from Gibco Laboratories (Grand
Island, New York, USA), and Sigma Chemical Co. (St. Louis,
Missouri, USA). Tissue culture plates and dishes were obtained
from Becton Dickinson and Co. (Oxnard, California, USA).
Epidermal growth factor (receptor grade-from mouse submax-
illary glands; EGF), platelet-derived growth factor (from human
platelets; PDGF), multiplication stimulating activity (from cul-
tured Buffalo rat liver cells; MSA), insulin-like growth factor 1
(human recombinant; IGF-l) and transforming growth factor-/3
(from human platelets; TGF-/3) were all obtained from Collab-
orative Research Inc. (Bedford, Massachusetts, USA). [125W
I]-EGF was obtained from New England Nuclear (Boston,
Massachusetts, USA).
Epithelial cell culture
Rat glomerular visceral epithelial cell (GEC) cultures were
established from the kidneys of male Sprague-Dawley rats
(Charles River Laboratories, Wilmington, Massachusetts,
USA), cloned and characterized as previously described [3, 21].
Cells were maintained and passaged on collagen gels in a 50:50
mixture of K 1 media (a defined epithelial cell growth mixture
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Fig. 2. Effect of insulin on GEC proliferation. GEC were grown in
K 1-0.5% FCS with (A) or without (•) insulin and various concentra-
tions of EGF as shown. Each point represents the mean SE of
triplicate determinations of cell number/well on day 3. For points
without error bars the SE was less than the symbol size.
in a hemocytometer following their removal from wells with
trypsin-EDTA. Stimulation of growth was assessed by compar-
ing the increase in cell number in experimental versus control
(Kl-0.5% FCS) wells. Cells in experimental wells did not
exceed 75 to 80% confluence when experiments were termi-
nated. All stimuli were evaluated in three to four wells per plate
and experiments were performed a minimum of two times.
Because the concentration of insulin present in K 1 media could
potentially interact with receptors for insulin-like growth fac-
tors, experiments involving these factors were also repeated in
Kl media lacking insulin.
Studies of growth inhibition
0 20 40 60 80 100 Cells were plated as above in Kl-3T3 media. TGF-/3 at the
EGF, ag/mi indicated concentrations was added after four to six hours and
change in cell number per well between days 1 and 3 determined
as above. Inhibition of growth was calculated as follows:
l-[(change in cell number in Kl-3T3 + TGF-f3)/(change in cell
number in Kl-3T3)]. The effect of time of exposure to TGF-/3 on
inhibition of GEC growth was also determined by exposing the
cells to TGF-J3 for the times indicated below.
Measurement of EGF binding
containing NaHCO3- 1.1 mg/mI) and conditioned media from
Swiss mouse 3T3 fibroblasts (Dulbecco's MEM with 10%
heat-inactivated fetal calf serum-FCS) [31. Experiments were
performed using cells plated on rat-tail collagen coated plates in
their 15th to 25th passage.
Studies of GEC proliferation
Cells were plated at a density of 10 to 20,000/cm2 on rat-tail
collagen coated multi-well plates in Kl media containing 0.5%
FCS. After the cells had adhered (4 to 6 hours) fresh media
containing various concentrations of the growth factors under
study was added. The growth factors and concentrations used
are given in Table 1 and Figure 1. The number of cells/well was
determined on day 1 and days 3 or 4 of growth by counting cells
Cells were plated at 10 to 20,000/cm2 on rat-tail collagen
coated plates in K1-3T3 media and allowed to grow for two days
prior to study. In some experiments TGF-/3 (final concentration
— 0.1 nglml) was added to cells four or 24 hours post-plating.
Wells were washed twice with binding medium (Dulbecco's
MEM + Ham's F12 (1:1) with 20 mM Hepes and 0.2% bovine
serum albumin, pH 7.2) and then pre-incubated in binding
medium for 45 minutes at 37°C with or without a 250- to 500-fold
excess of unlabelled EGF. '251-EGF (100 to 200 sCi/g; final
concentration 4 ng/ml) was added to all wells and incubation
continued for four hours at 0 to 4°C. Prior studies had demon-
strated that binding was maximal by this time and that TCA
precipitability of labeled EGF was constant during this period.
Cells were then washed four times with PBS with 0.1% BSA,
Table 1. Stimulation of GEC proliferation by growth factors 80
Factor
Relative increase
cell no. (mean
in
SE) N
EGF 10 ng/ml
EGF 100 ag/mI
2.7 0.2
3.3 0.2
6"
6"
IGF-l 100 ng/ml 0.7 0.2 6
MSA 100 ng/ml 1.2 0.1 6
PDGF5 U/mI 0.9 0.1 6
PDGF 10 U/mI 1.1 0.2 5
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GEC were plated in Kl-0.5% FCS. Fresh media with the indicated
growth factors was added after 4 to 6 hours. Cell number/well was
determined by visual counting on days 1 and 3 post-plating and the
increase in cell number with the factor compared to the increase in cell
number in Kl-0.5% FCS.
a Total number of wells studiedbP < 0.05 vs. control media
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Fig. 1. Prol(ferative response of GEC to EGF. GEC were grown in
K 1-0.5% FCS with or without EGF at the indicated concentrations and
the change in cell number/well from days 1 to 3 determined by visual
counting. The ordinate represents the relative increase in cell number in
EGF containing media compared to cells grown in K 1-0.5% FCS. Each
stimulus was evaluated in 3 wells/plate and the experiment was re-
peated twice. < 0.02 vs. control.
Fig. 3. Binding of '251-EGF to GEC. Symbols
are: (•) specific; (•) total, (A) non-specific.
A. GEC were incubated with increasing
amounts of labelled EGF (1-75 nglml) for 4
hours at 0°C. Non-specific binding was
determined in the presence of a 500-fold
excess of unlabelled EGF. CPM bound are
per 106 cells. Each point represents the mean
SE of triplicate determinations performed
twice. For points without error bars the SE
was less than the symbol size. B. Scatchard
EGF, ng/m/ transformation of the binding data.
solubilized in 1 N NaOH and transferred to tubes for counting.
Non-specific binding to cells under these conditions was always
<10%. Non-specific binding to the rat-tail collagen substrate
was below the limits of detection. To determine whether
changes in binding of '251-EGF reflected alterations in dissoci-
ation constant (Kd) or number of binding sites cells were
incubated as above, but with varying amounts of '251-EGF up to
75 nglml. All results are expressed as specific binding (total —
non-specific).
Analysis of results
All results are reported as mean SE. Comparisons of the
means of groups were made using Student's r-test or one-way
analysis of variance with post-hoc testing using the Tukey-
Kramer test as appropriate, employing Systat statistical soft-
ware (Systat Inc., Evanston, Illinois, USA). P values <0.5
were regarded as significant. Scatchard analysis of binding data
was performed using the LIGAND program adapted for micro-
computers (Elsevier Science Publishers By, Amsterdam, Neth-
erlands).
Results
Response of GEC to growth factors
The response of GEC to the growth factors studied is
summarized in Table 1 and Figure 1. GEC proliferated in
response to EGF with approximately a threefold maximum
increase in proliferation compared to cells growing in K1-0.5%
FCS (Fig. 1). A maximal response was seen with approximately
10 ng/ml EGF. No significant proliferative response was seen
with MSA, IGF-1 or PDGF (Table 1). Because Ki media
contains insulin (10 g/m1) we also evaluated the response of
GEC to EGF, MSA and IGF-l in media without insulin. EGF
was still able to promote GEC growth in the absence of insulin
but an approximately twofold increase of cell number was seen
in the presence of insulin at all levels of EGF studied (Fig. 2).
MSA and IGF-1 still failed to stimulate GEC proliferation in this
media (data not shown). Addition of IGF- 1, MSA, PDGF,
IGF-l + PDGF, or MSA + PDGF to media containing EGF did
not produce any further stimulation of growth above that
obtained with EGF whether or not insulin was present in the
media (data not shown).
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Fig. 4. Competition for binding of'251-EGF to GEC. Symbols are: (•)
EGF; (A) insulin; () TGF-13. GEC were incubated with '231-EGF (4
ng/ml) and increasing amounts of unlabelled competing ligand. Each
point represents the mean SE of triplicate determinations performed
twice.
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Table 2. Efffect of TGF-/3 on binding of '251-EGF to GEC
EGF binding to GEC
'251-EGF bound to GEC in a dose-dependent, saturable
manner (Fig. 3A). Non-specific binding in the presence of a
500-fold excess of EGF was <10% except at the highest
concentrations of '251-EGF used. Approximately 50% of the
bound growth factor could be displaced within two hours by a
250-fold excess of cold EGF. Scatchard analysis of the binding
data revealed a best fit to a one-site model with a dissociation
constant (Kd) of approximately 1.7 nM and an apparent number
of binding sites of 86,000/cell (Fig. 3B). Binding could be
competitively inhibited by unlabelled EGF but not by other
peptide growth factors such as insulin and TGF-f (Fig. 4).
Effect of TGF-/3 on GEC growth
Addition of TGF-/3 to GEC in Kl-3T3 four to six hours
following plating resulted in a dose-dependent inhibition of
growth measured on the third day (Fig. 5). Addition of EGF (10
ng/ml) at the same time as TGF-/3 was not able to overcome this
growth inhibitory effect (data not shown). When GEC were
grown in Kl-0.5% FCS supplemented with EGF (I ng/mI) a
similar inhibition of growth by TGF-f3 was seen (38.0 6.8%
inhibition at 0.1 ng/ml TGF-f3; >90% inhibition at 1.0 ng/ml
TGF-/3). The time course of the effect of TGF-/3 on GEC growth
was analyzed by exposing cells for different time periods during
the three day period of study (Fig. 6). Exposure of GEC to
TGF-/3 from 4 to 24 hours or from 4 to 72 hours of culture
resulted in a significant decrease in cell number/well on day 3 (P
<0.001). However, the decrease in cell number/well on day 3
was similar with both of these conditions (P> 0.4), suggesting
that a relatively brief, early period of exposure is necessary to
Time of
exposure
CPM bound
Control TGF-f3
4 to 48 Hours 16304 1103 27358 1419
24 to 48 Hours 13130 1132 13925 1089
GEC were plated in K1-3T3 media and grown in the presence of
TGF-j3 (0.1 ng/ml) for the indicated times. Specific binding of '251-EGF
(4 ng/ml) was determined following 48 hours of growth. The values
shown are mean SE of specific CPM bound per 106 cells in triplicate
wells. The experiment was repeated twice with similar results.
a P < 0.05 vs. control
achieve maximal inhibition of cell growth. Exposure of cells to
TGF-/3 from 24 to 48 or 48 to 72 hours of the culture period
produced progressively less inhibition of growth. Neither of
these exposure times resulted in a significant decrease in cell
number/well on day 3 (P > 0.2).
Effect of TGF-f3 on binding of EGF to GEC
In view of the significant growth inhibitory effect of TGF-/3 on
GEC and the importance of EGF in promoting growth of these
cells we examined whether TGF-/3 might be acting by altering
binding of EGF to its receptor on GEC. Cells growing in
Kl-3T3 media were exposed to TGF-p (0.1 ng/ml) beginning
either 4 or 24 hours following plating and binding of EGF (4
ng/ml) was assessed after 48 hours of growth. Addition of
TGF-/3 24 hours after plating did not result in any significant
change in the amount of EGF bound (Table 2). However,
addition of TGF-/3 four hours after plating and continued
exposure for the remaining 48 hours of growth did lead to a
significant increase in binding (P <0.05).
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Fig. 5. Effect of TGF-J3 on GEC growth. Cells were plated in K1-3T3
media and TGF-13 at the concentrations shown added after 4 to 6 hours.
Inhibition of growthwas determined from visual counts of cells on days
I and 3. Each point represents the mean SE of quadruplicate
determinations. The experiment was repeated twice with similar re-
sults.
4—72 4—24 24—48 48—72 None
Time of exposure, hours
Fig. 6. Effect of time of exposure to TGF-/3 on GEC growth. GEC were
plated in K1-3T3 media. TGF-)3 (0.1 ng/ml) was present in the media
during the indicated time periods. Cell number/well was similar on day
I for all the conditions studied. Cell number/well following 72 hours of
growth was determined by visual counting. Each bar represents the
mean SE of cells/well in 6 wells, and the experiment was repeated
twice with similar results. (P < 0.001 vs. no exposure to TGF-/3; tP
> 0.2 vs. no exposure to TGF-13).
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Fig. 7. Effect of TGF-$ exposure on binding of EGF to GEC. A. GEC
were grown for two days in K1-3T3 media in the presence of (A) or
absence (S) ofTGF-/3 0.1 ng/ml. Each point represents the mean SE
of '251-EGF CPM bound per 106 cells in triplicate wells in two separate
experiments. EGF binding was significantly greater in TGF-f3 treated
cells at each level of EGF assayed (P < 0.01). B. Scatchard analysis of
the binding data represented in A.
To determine whether this increase in binding of EGF repre-
sented an increase in number of cell surface EGF receptors or
a change in the affinity of the receptor for EGF we performed
saturation binding studies. GEC exposed to TGF-f3 (0.1 ng/ml)
for 48 hours of culture were incubated with increasing amounts
of '251-EGF (1 to 50 nglml) and specific binding determined.
EGF binding was significantly increased by TGF-$ exposure at
each level of EGF added (P < 0.01; Fig. 7A). Scatchard
analysis of the data (Fig. 7B) revealed similar Kd's (1.65 flM
control; 1.40 nM TGF-/3) but a rise in the mean number of
apparent binding sites per cell (85878 control; 203242 TGF-/3).
Separate studies measuring binding of EGF to GEC at different
cell densities per well showed a slight decrease in EGF binding
with lower densities, suggesting that fewer cells per well in
cultures exposed to TGF-f3 could not account for the observed
rise in EGF binding (data not shown).
Discussion
The results presented here demonstrate that EGF is an
important stimulus to GEC proliferation but that several other
growth factors studied, including IGF-1, MSA and PDGF,
failed to stimulate GEC growth. This is in contrast to glomer-
ular mesangial cells which proliferate in response to several
growth factors and cytokines. Saturation binding studies of
'251-EGF to GEC reveal the presence of a single subclass of
saturable binding sites with high affinity for EGF. This binding
can be displaced by cold EGF but not by other polypeptide
growth factors such as insulin or TGF-f3. EGF receptors have
also been demonstrated on intact rabbit glomeruli [23] and on
glomerular mesangial cells, where they mediate several re-
sponses to EGF including growth, contraction and stimulation
of Na/H exchange [12]. A role for EGF stimulated Na/H
exchange in mediating cell proliferation in our experiments,
however, is unlikely as they were performed in HC03 con-
taining media.
EGF may potentially be released during the course of gb-
merular injury from several sources. Both platelets and macro-
phages can produce EGF or EGF-like molecules [13, 241. The
presence of platelet fragments and platelet related antigens has
been well established in several types of human and experimen-
tal glomerular disease [25, 261. The presence of mononuclear
cells and macrophages in glomeruli during the course of gb-
merulonephritis has been well demonstrated and they are also
known to be an important constituent of glomerular crescents
[20, 27]. The temporal association between macrophage ingress
into glomeruli and the appearance of crescents has been taken
as suggestive evidence that macrophage products may stimulate
crescent formation, although the contribution of visceral epi-
thelial cells, especially to inflammatory crescents, is not univer-
sally accepted [20]. Fibrin deposition in the urinary space has
been widely held to be a stimulus to crescent formation; the
evidence for this is indirect [28, 29]. Direct measurement of the
effect of fibrinogen/fibrin and its breakdown products on GEC
has not been done but the only effect seen on proliferation of
gbomerular mesangial cells was toxicity of some of the fibrin
degradation products [30]. Release of EGF from macrophages
is one potential mechanism whereby GEC might be stimulated
to proliferate in vivo. Finally, the kidney itself is an important
site of prepro-EGF production, although the localization of
most of this to the thick ascending limb of the loop of Henle and
the distal convoluted tubule do not readily suggest a pathway
for it to reach glomerular cells [31, 32].
TGF-/3 was found to have a potent inhibitory effect on GEC
growth, as it has on several other cell types including murine
GEC [18, 33]. This effect is long lasting and occurs after a
relatively brief exposure, similar to that observed in rat hepa-
tocytes [34]. We did not find stimulation of growth by TGF-/3 at
higher cell densities (unpublished observations) as has been
reported by others with murine mesangial and rat aortic smooth
muscle cells [18, 35], but did confirm the finding that TGF-13
inhibits EGF stimulated growth of GEC as noted in murine
GEC [18]. The inhibitory effect of TGF-f3 on GEC growth
appears to occur independently of short term alterations in the
IA
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EGF receptor. Up to 24 hours of exposure to TGF-/3 produces
no alteration in binding of '251-EGF to GEC despite maximal
inhibition of growth, and addition of EGF does not reverse the
effect of TGF-/3. This would suggest that the action of TGF-f3
occurs at a later stage in the sequence of events leading to
growth factor-induced cell proliferation. However, more pro-
longed exposure to TGF-f3 (44 hours) does increase the appar-
ent number of EGF binding sites per cell. Other studies of the
effects of TGF-/3 on EGF binding to cells have found either no
effect [34, 36], decreased binding [37], increased binding [38] or
a biphasic effect [39]. The studies performed here do not allow
us to distinguish between an effect of TGF-/3 on receptor
synthesis versus receptor internalization and recycling as an
explanation for the increased binding at 48 hours.
In previous studies we examined the effect of several growth
factors on GEC whose growth had been inhibited by heparin
and found that EGF was capable of partially reversing heparin's
effect [22]. In contrast to the inhibitory action of TGF-/3 on
GEC, heparin's effect is, as noted, partially reversible by EGF
and is associated with an increase in receptor affinity for EGF
without any apparent change in number of receptors per cell.
This, and the observation of a slight decrease in EGF binding
with lower cell densities (unpublished observations) suggests
that the increase in EGF binding to GEC exposed to TGF-/3 for
prolonged periods is not simply a consequence of inhibited
growth but must represent a specific effect of TGF-/3. The
significance of this finding for EGF action, however, is not
clear.
It is likely that TGF-13 is released during the course of
glomerular injury from the same sources as EGF. Platelets are
a rich source of TGF-/3 [40] and it has also been shown to be
secreted by activated macrophages [41]. Furthermore, its pres-
ence has been detected in bovine kidney although its site of
synthesis in the kidney has not been determined [42]. Whether
it plays any physiologic role in modulating glomerular cell
proliferation in vivo during the course of glomerular injury is
unknown.
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